Close

Aegis Capital Affirms Neuralstem (CUR) at 'Buy' Following Q2 Numbers; Plenty of Clinical Milestones Await

August 8, 2014 11:48 AM EDT Send to a Friend
Aegis Capital keeps Neuralstem (AMEX: CUR) at Buy with a $7 price target following Q2 results released earlier.Neuralstem posted Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login